{"created":"2023-06-19T10:21:48.253797+00:00","id":772,"links":{},"metadata":{"_buckets":{"deposit":"9e84b680-6207-495c-a76c-ffd13c3e8e51"},"_deposit":{"created_by":12,"id":"772","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"772"},"status":"published"},"_oai":{"id":"oai:saitama-med.repo.nii.ac.jp:00000772","sets":["9:7:123"]},"author_link":["2522","2526","2527","2518","2523","2530","2534","2517","2533","2531","2532","2529","2524","2525","2521","2519","2528","2520"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"14","bibliographicPageStart":"9","bibliographicVolumeNumber":"46","bibliographic_titles":[{"bibliographic_title":"埼玉医科大学雑誌"},{"bibliographic_title":"Journal of  Saitama Medical University ","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【緒言】CheckMate025第III相試験において,転移性腎細胞癌(metastatic renal cell carcinoma:mRCC)に対する二次治療としてのニボルマブの臨床効果の改善が示された.今回我々は,当院におけるmRCCに対するニボルマブの短期的な効果と安全性について後方視的検討を行った.【対象と方法】2016年12月から2017年12月の間,28例のmRCCに対してニボルマブを投与した.CheckMate025試験と異なり,非淡明細胞成分を有する症例や3種類以上の分子標的薬が投与された症例が含まれていた.RECIST version1.1に基づき,3名の測定者によって腫瘍縮小効果を検討した.【結果】経過観察期間の中央値は7.1ヵ月(四分位範囲:3.8-10.3)であった.全生存期間および無増悪生存期間の中央値は11.7ヵ月と6.1ヵ月であった.客観的奏効率(ORR:完全完解率+部分寛解率)は8.3%であり,臨床的有用率(ORR+安定率)は75.0%であった.ニボルマブ関連有害事象は50.0%,とくにGrade3以上は3.6%の症例に認められた.【結論】本検討は,少数のコホートであるが,mRCCに対するニボルマブ療法の有用性と安全性が示された.(著者抄録)\n\n【Purpose】 The phase III CheckMate 025 trial showed that nivolumab improved clinical benefit in advanced renal cell carcinoma. Herein, we report the efficacy and safety of nivolumab for metastatic renal cell carcinoma (mRCC) patients in a Japanese single institution. 【Material and Methods】 Twenty-eight mRCC patients who had failed prior molecular targeted therapy (MTT) were treated with nivolumab between December 2016 and December 2017. Our cohort included heterogeneous cases with non-clear cell carcinoma, three or more prior lines of MTT, and a higher proportion in the poor risk group. 【Results】 Median overall survival and progression-free survival were 11.7 and 6.1 months, respectively. The objective response rate and clinical benefit rate were 8.3 and 75.0%, respectively; one case achieved complete response. Any-grade and severe nivolumab-related adverse events in our cohort accounted for 50.0 and 3.6%, respectively. 【Conclusion】 The current results showed the usefulness of nivolumab treatment for mRCC patients, regardless of the small cohort with heterogeneous characteristics studied.","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"埼玉医科大学医学会"}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"埼玉医科大学雑誌"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.saitama-med.ac.jp/jsms/vol46/jsms46_09-14.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN0009506X","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0385-5074","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_24":{"attribute_name":"記事区分","attribute_value_mlt":[{"subitem_text_value":"原著 / original"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"城武, 卓"},{"creatorName":"シロタケ, スグル","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2517","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"近藤, 秀幸"},{"creatorName":"コンドウ, ヒデユキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2518","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"林, 泰樹"},{"creatorName":"ハヤシ, タイキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2519","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡部, 尚志"},{"creatorName":"オカベ, タカシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2520","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高橋, 崇志"},{"creatorName":"タカハシ, タカユキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2521","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高橋, 美賀"},{"creatorName":"タカハシ, ミカ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2522","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"金子, 剛"},{"creatorName":"カネコ, ゴウ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2523","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"西本, 紘嗣郎"},{"creatorName":"ニシモト, コウシロウ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2524","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小山, 政史"},{"creatorName":"オヤマ, マサフミ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2525","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shirotake, Suguru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2526","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kondo, Hideyuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2527","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hayashi, Taiki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2528","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okabe, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2529","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahashi, Takayuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2530","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahashi, Mika","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2531","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kaneko, Go","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2532","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishimoto, Koshiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2533","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Oyama, Masafumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2534","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-10-28"}],"displaytype":"detail","filename":"jsms46_1_09-14.pdf","filesize":[{"value":"623.0 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"埼玉医科大学雑誌46巻1号9-14頁","url":"https://saitama-med.repo.nii.ac.jp/record/772/files/jsms46_1_09-14.pdf"},"version_id":"b1492f21-8e7d-4be6-bc5e-a8cca2b9ea55"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"関節炎(化学的誘発)","subitem_subject_scheme":"Other"},{"subitem_subject":"コホート研究","subitem_subject_scheme":"Other"},{"subitem_subject":"MRI","subitem_subject_scheme":"Other"},{"subitem_subject":"*腎細胞癌(画像診断,薬物療法,予後)","subitem_subject_scheme":"Other"},{"subitem_subject":"X線CT","subitem_subject_scheme":"Other"},{"subitem_subject":"肺腫瘍(転移性)","subitem_subject_scheme":"Other"},{"subitem_subject":"Karnofskyスケール","subitem_subject_scheme":"Other"},{"subitem_subject":"後向き研究","subitem_subject_scheme":"Other"},{"subitem_subject":"第III相試験","subitem_subject_scheme":"Other"},{"subitem_subject":"Kaplan-Meier法","subitem_subject_scheme":"Other"},{"subitem_subject":"*Nivolumab(治療的利用,毒性・副作用)","subitem_subject_scheme":"Other"},{"subitem_subject":"無増悪生存","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト","subitem_subject_scheme":"Other"},{"subitem_subject":"成人(19〜44)","subitem_subject_scheme":"Other"},{"subitem_subject":"中年(45〜64)","subitem_subject_scheme":"Other"},{"subitem_subject":"高齢者(65〜79)","subitem_subject_scheme":"Other"},{"subitem_subject":"高齢者(80〜)","subitem_subject_scheme":"Other"},{"subitem_subject":"男","subitem_subject_scheme":"Other"},{"subitem_subject":"女","subitem_subject_scheme":"Other"},{"subitem_subject":"renal cell carcinoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"nivolumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"outcome","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"当院における転移性腎細胞癌に対するニボルマブの初期使用経験","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"当院における転移性腎細胞癌に対するニボルマブの初期使用経験"},{"subitem_title":"Efficacy and safety of nivolumab for metastatic renal cell carcinoma: Japanese single institutional retrospective study","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"12","path":["123"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-10-28"},"publish_date":"2021-10-28","publish_status":"0","recid":"772","relation_version_is_last":true,"title":["当院における転移性腎細胞癌に対するニボルマブの初期使用経験"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-06-19T10:29:52.208721+00:00"}